Actos prevents diabetes in high-risk people

10:36, March 25, 2011      

Email | Print | Subscribe | Comments | Forum 

A new study has found that Actos, a medicine treats onset diabetes, could also reduce the diabetes risk in people with prediabetes.

The study, which was published Wednesday in New England Journal of Medicine, followed 602 prediabetics whose obesity, ethnicity, family history and other factors put them at high risk of developing diabetes.

The research findings showed that Actos, generically known as pioglitazone, reduced the odds of developing Type 2 diabetes by 72 percent in people with prediabetes.

Only 2.1 percent of those who took Actos developed diabetes each year over the three years of the study, compared with 7.6 percent of those who took a placebo.

Lead author of the study Ralph DeFronzo said, "The 72 percent reduction is the largest decrease in the conversion rate of pre-diabetes to (Type 2) diabetes that has ever been demonstrated by any intervention, be it diet, exercise or medication."

However, Actos can have significant side effects, including water retention, moderate weight gain, and increased risk of bone fractures.

Source: Xinhua/Agencies
  Weekly review  


  • Do you have anything to say?


Special Coverage
  • Survey for 2011 NPC and CPPCC Sessions
  • Focus On China
Major headlines
Editor's Pick
  • Li Xiaoxia wins single final in Guangzhou Volkswagen Cup
  • 128-year-old church to be moved
  • Wang Hao wins Volkswagen Cup in Guangzhou
  • Anti-president protestors hold rally in Yemen
  • Gaddafi's supporters hold rally in Libya
  • China Fashion Week kicks off in Beijing
Most Popular
Hot Forum Dicussion